Table 1 Selected characteristics (at the end of follow-up) of participants according to ever use of progestagens (n=73 664) E3N cohort study (1990–2002)
From: Oral progestagens before menopause and breast cancer risk
Non-users n =45 294 | Users n =28 370 | |
|---|---|---|
n (%) | n (%) | |
Year of birth | ||
1925–1937 | 18 402 (40.62) | 5030 (17.72) |
1938–1944 | 11 024 (24.33) | 9109 (32.10) |
1945–1951 | 15 868 (35.05) | 14 231 (50.18) |
History of BC (first degree relatives) | ||
None | 40 191 (88.73) | 25 027 (88.21) |
1 | 4 640 (10.24) | 3 074 (10.83) |
2 and + | 463 (1.03) | 269 (0.96) |
History of BC (second degree relatives) | ||
No | 38 717 (85.47) | 23 755 (83.73) |
Yes | 6577 (14.53) | 4615 (16.27) |
History of BUOD a | ||
No | 27 199 (60.04) | 14 096 (49.68) |
Yes | 18 095 (39.96) | 14 274 (50.32) |
History of BBD a | ||
No | 35 122 (77.54) | 18 418 (64.92) |
Yes | 10 172 (22.46) | 9 952 (35.08) |
Body mass index (premenopausal, kg m−2) | ||
<22 | 279 (0.61) | 148 (0.52) |
22–25 | 43 451 (95.93) | 27 257 (96.07) |
25–30 | 1214 (2.68) | 772 (2.72) |
>30 | 350 (0.78) | 193 (0.69) |
Age at menarche (years) | ||
<13 | 20 798 (45.91) | 13 369 (47.12) |
13–15 | 22 653 (50.01) | 14 134 (49.82) |
>15 | 1843 (4.08) | 867 (3.06) |
Parity | ||
Nulliparous | 5450 (12.03) | 3028 (10.67) |
Age at first FTP>30 num=1b | 1 836 (4.05) | 1 101 (3.88) |
Age at first FTP>30 num>1 | 1981 (4.37) | 1129 (3.97) |
Age at first FTP<= 30 | 36 027 (79.55) | 23 112 (81.48) |
OC use | ||
Never | 31 606 (69.77) | 14 927 (52.61) |
Ever | 13 688 (30.23) | 13 443 (47.39) |
Age at menopause c (years) | ||
<48 | 9871 (25.23) | 4429 (18.24) |
48–52 | 19 990 (51.09) | 12 995 (53.53) |
>52 | 9266 (23.68) | 6853 (28.23) |
HRT use c | ||
Never | 14 541 (37.16) | 2679 (11.04) |
Ever | 24 586 (62.84) | 21 598 (88.96) |
Mammographic history | ||
Never | 9660 (21.32) | 2775 (9.78) |
Ever | 35 634 (78.68) | 25 595 (90.22) |
